retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity is gaining attention in metabolic research for its activity on GIP, GLP-1, and receptors. In this carousel, we summarize recent clinical study findings related to weight management, type When the Breakthrough Obesity G-Agonist
Description
Larger Phase 3 trials are required before regulatory approval can be sought, and results in real-world clinical practice may differ from those observed under trial conditions
Suvarna R, P
Regulating Blood Sugar Levels: GLP-1 medications promote insulin release from the pancreas when blood sugar is elevated
Researchers found that semaglutide users were twice as likely to develop nAMD compared to non-users, even after adjusting for other health factors
